« Return to News | Clinical Intelligence

Researchers use stem cells to determine new therapies for severe childhood epilepsy

Tuesday, December 6, 2011 01:52 PM
A U-M team of researchers investigating the fundamental cause of Dravet syndrome, a severe childhood epilepsy, have reprogrammed fibroblasts, a type of skin cell, from Dravet patients and generated patient-specific neurons- which could help determine new therapies or better medications for the syndrome.
 
Jack M. Parent, M.D., working in collaboration with Lori Isom, Ph.D., and Miriam Meisler, found that these patient-derived neurons showed increased excitability, abnormal neuronal behavior that can produce seizures.
 
Parent, who is also co-director of U-M's EEG/Epilepsy Program, and his team obtained fibroblasts from both Dravet patients and unaffected controls and reprogrammed the cells to induced pluripotent stem cells (iPSCs) by gene transfer.
 
Forebrain-like neurons were generated from the iPSCs and studied for their
electro-physical properties. The Dravet-derived neurons displayed a lower
threshold for electrical activity, more repetitive firing, and increased firing frequency than control neurons.
 
"These findings indicate that patient-specific mutant Dravet cells can be reprogrammed to successfully model an epileptic-like phenotype with in vitro seizure-like activity," Parent says.
 
"Besides providing new insight into disease pathogenesis, this approach using patient-specific cells should prove a valuable tool to evaluate potential new medications for Dravet syndrome and potentially other developmental epilepsies," added Parent.
Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.